Compound 19

JAK1/TYK2-selective dual kinase inhibitor

oral activity in arthritis model

from SBDD of prior internal matter

Bioorg. Med. Chem. Lett., Mar. 31, 2020

Pfizer, Cambridge, MA and Groton, CT

“Compound 19” is a JAK1/TYK2 dual kinase inhibitor from Pfizer, related to its clinical JAK1/TYK2 dual inhibitor, brepocitinib, in Ph. II for a variety of inflammatory diseases. The cyclopropyl amide…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.